FMI predicted the CRISPR-integrated gene editing delivery devices market was valued at USD 1.03 billion in 2025. The industry is expected to cross USD 1.18 billion in 2026 and USD 4.41 billion by 2036. Electroporation/flow electroporation systems are poised to lead by delivery platform type with 34.0% share in 2026 and CRISPR RNP delivery is poised to dominate by payload format through 2036.